cd19 microbeads (Miltenyi Biotec)
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
96
Structured Review
Miltenyi Biotec
cd19 microbeads
Cd19 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 926 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd19/CD19+MicroBeads%2C+mouse/bio_rxiv__64898__2026__10__12__756217-223-7-9
Average 96 stars, based on 926 article reviews
Cd19 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 926 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd19/CD19+MicroBeads%2C+mouse/bio_rxiv__64898__2026__10__12__756217-223-7-9
Average 96 stars, based on 926 article reviews
cd19 microbeads - by Bioz Stars,
2026-11
96/100 stars
Images
1) Product Images from "Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures"
Article Title: Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures
Journal: bioRxiv
doi: 10.64898/2026.10.12.756217
Figure Legend Snippet: a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Techniques Used: Xenograft Assay, Immune Cell
Figure Legend Snippet: a, H&E staining of tumor sections from combination treatment groups. b, Multiplex immunofluorescence staining for CD3, CD19, CD23, and CD31 on tumor sections from the combination treatment group. c, Multiplex immunofluorescence staining for CD138, IgG and IgA on tumor sections from vehicle and combination treatment groups. d, Quantification of the CD138+ cell / mm 2 and IgG/IgA ratio in tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. e, UMAP plots of B cells at indicated time points post-treatment. f, BCR repertoire diversity, clonal dynamics, and SHM following combination treatment. g, Immunoglobulin isotype distribution of B cells over the treatment time course. h, Peripheral BCR repertoire diversity and SHM following combination treatment. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Techniques Used: Staining, Multiplex Assay, Immunofluorescence
Figure Legend Snippet: a, Experimental schematic of the in vivo depletion and adoptive transfer study design. b, Tumor growth curves of mice treated with the combination regimen following depletion of B cells, CD4+ T cells, CD8+ T cells, NK cells, or FcyR blockade. n = 5-8 mice per group. c, Multiplex immunofluorescence staining for C3d, IgG, and CK8/18 on tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. d, Quantification of memory B cells in the spleen and tumor-draining lymph nodes from vehicle and combination treatment groups by flow cytometry. n = 4 per group. e, Quantification of long-lived plasma cells in the bone marrow from vehicle and combination treatment groups by flow cytometry. n = 5 per group. f, Serum levels of tumor-specific antibodies measured by flow cytometry in vehicle and combination treatment groups. n = 3-5 per group. g, (Left) Quantification of plasma cells generated from CD19+ splenocytes stimulated with tumor antigens in vitro. (Right) IgG binding to tumor cells detected by flow cytometry after incubation with culture supernatants from vehicle or combination treatment groups. h, Tumor volume curves of naive recipient mice receiving adoptive transfer of B cells or T cells from vehicle- or combination-treated donor mice, followed by tumor inoculation and half-dose RMC-6236 administration. n = 7 mice per group. i, Rechallenge tumor growth in non-CR and treatment-naive mice. n = 8 mice per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Techniques Used: In Vivo, Adoptive Transfer Assay, Multiplex Assay, Immunofluorescence, Staining, Flow Cytometry, Clinical Proteomics, Generated, In Vitro, Binding Assay, Incubation
Related Articles
Incubation:Article Title: Tissue Factor-inhibited Beclin1-autophagy via BCL2 overexpression suppresses the differentiation of human monocytes into mature osteoclasts Article Snippet: .. PBMCs were incubated with CD3 (130-050-101, Miltenyi), Isolation:Article Title: Single domain antibodies and their use in cancer therapies Article Snippet: T Cell Isolation and Transduction Peripheral blood mononuclear cells (PBMCs) were recovered using the density gradient LymphoprepTM (StemCells). .. CD8+ T cells were isolated by negative selection using a cocktail containing antibodies against CD4, CD15, CD16, Article Title: Distinct contribution of autoreactive B cell Bruton’s tyrosine kinase signaling to neuroinflammation Article Snippet: .. Both B cells and T cells were isolated through positive selection using Selection:Article Title: Single domain antibodies and their use in cancer therapies Article Snippet: T Cell Isolation and Transduction Peripheral blood mononuclear cells (PBMCs) were recovered using the density gradient LymphoprepTM (StemCells). .. CD8+ T cells were isolated by negative selection using a cocktail containing antibodies against CD4, CD15, CD16, Article Title: Distinct contribution of autoreactive B cell Bruton’s tyrosine kinase signaling to neuroinflammation Article Snippet: .. Both B cells and T cells were isolated through positive selection using other:Article Title: Pre-existing neutralizing antibodies against cattle-transmitted influenza A virus H5N1 are detectable in unexposed individuals. Article Snippet: Staining:Article Title: Early-stage B cells predict relapse after rituximab treatment in patients with Membranous Nephropathy Article Snippet: .. To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), Article Title: Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy Article Snippet: .. To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), Bioprocessing:Article Title: Early-stage B cells predict relapse after rituximab treatment in patients with Membranous Nephropathy Article Snippet: .. To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), Article Title: Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy Article Snippet: .. To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), |